Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. 1997

E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
Department of Obstetrics and Gynecology, University of Wisconsin, Madison 53792, USA.

Vascular endothelial growth factor (VEGF) expression and microvessel density were studied in cases of advanced epithelial ovarian carcinoma to evaluate their usefulness as prognostic variables. Tumor samples from 18 patients with advanced stage serous epithelial ovarian cancer were evaluated for VEGF expression by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Immunohistochemical study of corresponding archival tissues with an antibody to von Willebrand factor (vWF; FVIII-RA) was used for tumor microvessel count determinations. The correlation of VEGF expression and mean microvessel counts was determined by an unpaired t-test. Survival analysis for known prognostic factors and VEGF expression was performed. Survival distributions were calculated by the product limit of Kaplan and Meier and significant differences between distributions were analyzed with a log rank test. From the RT-PCR analysis of tumor VEGF expression, 12 samples were found to be strongly positive, whereas six samples had low/negative VEGF expression. The median survival was 60 months for the VEGF-low/negative group and 28 months for the VEGF-positive group (P = 0.058). Other prognostic variables had minimal impact on survival, i.e. age < 65 years (P = 0.873), FIGO stage (P = 0.06), grade (P = 0.236) and debulking status (P = 0.842). Fourteen of 18 tumor specimens were suitable for microvessel counting. The mean microvessel counts of the VEGF-positive group and the VEGF-negative group were 27/hpf and 35/hpf, respectively (P = 0.16). In this preliminary analysis, high VEGF expression in epithelial ovarian carcinomas was associated with poor overall survival. Further study will be necessary to elucidate the lack of association of VEGF expression and tumor microvessel counts.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004848 Epithelium The layers of EPITHELIAL CELLS which cover the inner and outer surfaces of the cutaneous, mucus, and serous tissues and glands of the body. Mesothelium,Epithelial Tissue,Mesothelial Tissue,Epithelial Tissues,Mesothelial Tissues,Tissue, Epithelial,Tissue, Mesothelial,Tissues, Epithelial,Tissues, Mesothelial
D005260 Female Females

Related Publications

E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
November 2006, Ginekologia polska,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
January 1999, Endocrine pathology,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
December 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
January 1997, British journal of cancer,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
January 2015, Journal of cancer research and clinical oncology,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
February 2011, Anticancer research,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
May 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
June 2000, Medical and pediatric oncology,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
July 1998, Pathology international,
E M Hartenbach, and T A Olson, and J J Goswitz, and D Mohanraj, and L B Twiggs, and L F Carson, and S Ramakrishnan
May 2009, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Copied contents to your clipboard!